Summary
The Hepatitis Market Outlook to 2015 provides comprehensive coverage of the hepatitis market, incorporating disease overview and detailed epidemiological analyses of the various hepatitis types. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands, in order to enable the reader to identify growing brands, key drug classes and leading players through 2015. The Hepatitis market may be classified as viral and non- viral hepatitis, on the basis of causative agents. Out of the six different kinds of viral hepatitis, A, B, C, D, E, and G, hepatitis A, B and C remains the most common infections prevalent across the globe.
The Hepatitis Market Outlook to 2015: Competitive landscape, market size, pipeline analysis and growth opportunities
Despite, a significant number of Hepatitis cases going unreported due to the asymptomatic nature of the disease about 1.4m cases of acute hepatitis A are reported every year while the number of chronic hepatitis B cases is 350m and hepatitis C is 170m. Hepatitis C has become one of the major focus areas for pharmaceutical companies because of high number of unmet needs for improved treatments. Although, most of the hepatitis infected population is in underdeveloped or developing countries, the market share of these countries in the global hepatitis market is relatively lower, due to the limited access to healthcare facilities resulting in significant un-diagnosed population. In terms of product pipeline, the hepatitis market has witnessed a lot of activity, with promising new drugs under late stages of development. The potential for market success is largely attributable to a large patient population, which requires long term treatment, and significant unmet need. Hepatitis C is the major indication in the hepatitis market with promising products in development. Presently, pegylated interferon commonly used in combination with the ribavirin is the standard of care for hepatitis C treatment.
This report provides in depth coverage of the hepatitis market, incorporating a disease overview and detailed epidemiological analyses of the various hepatitis types. It makes a thorough assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. It highlights the key market trends that will drive sales. rbhc0285
Scope of this research
- Develop insight into hepatitis patient potential with coverage of epidemiology of all major hepatitis types in the seven major pharmaceutical markets.
- Discover how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the market.
- Compare the franchises of top pharmaceutical marketers, and evaluate how the market shares of the leading companies will change over the next 5 years.
- Gain up-to-date competitive intelligence on the hepatitis market and understand the major issues affecting its growth.
- Analyze the pipeline and marketed products of leading players and discover which will perform best through to 2015 with this report’s sales forecasts.
Research and analysis highlights
The global hepatitis market in 2009 was valued at around $5bn, and is forecast to grow at a CAGR of more than 10% between 2009–15. These sales are being driven by products in the viral hepatitis class.
Sales in the hepatitis market are largely concentrated in the top 10 brands. These brands accounted for more than 80% of total sales. The leading product by sales in this market was Roche’s Pegasys followed by Merck’s Pegintron.
New pipeline compounds are expected to shorten treatment duration and improve the side effect and tolerability profile of treatment. The two most promising developmental products are telaprevir (J&J, Vertex) and boceprevir (Merck & Co) both indicated for hepatitis C.
Key reasons to purchase this research
- How is the prevalent population for hepatitis expected to change in the next five years?
- Which companies led the market for hepatitis therapies in 2009 and how are they forecast to perform through to 2015?
- What are the most promising products in development for the treatment of hepatitis and what are their forecast sales?
- How big is the generics market for hepatitis in the 7MM and which companies lead this market?
- Which vaccines lead the market for hepatitis vaccination and which companies market these products?
